Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Dec 21, 2009; 15(47): 5946-5952
Published online Dec 21, 2009. doi: 10.3748/wjg.15.5946
Published online Dec 21, 2009. doi: 10.3748/wjg.15.5946
Table 4 Side effects occurring during 48 wk of treatment n (%)
| PR group (n = 15) | PK group (n = 16) | PRK group (n = 14) | P-value | |
| Anemia | 8 (53) | 7 (44) | 11 (79) | NS |
| Neutropenia | 9 (60) | 7 (44) | 10 (71) | NS |
| Arthro-myalgia | 4 (27) | 4 (25) | 5 (36) | NS |
| Headache | 3 (20) | 3 (19) | 2 (14) | NS |
| Fatigue | 5 (33) | 5 (31) | 4 (29) | NS |
| Flu-like symptoms | 4 (27) | 4 (25) | 2 (14) | NS |
| Psychiatric disorders | 5 (33) | 4 (25) | 4 (29) | NS |
| Gastrointestinal disorders | 6 (40) | 3 (19) | 4 (29) | NS |
| Pruritus | 4 (27) | 1 (6) | 0 | NS |
| Insomnia | 2 (13) | 2 (12.5) | 2 (14) | NS |
- Citation: Gramenzi A, Cursaro C, Margotti M, Balsano C, Spaziani A, Anticoli S, Loggi E, Salerno M, Galli S, Furlini G, Bernardi M, Andreone P. Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: A phase II study. World J Gastroenterol 2009; 15(47): 5946-5952
- URL: https://www.wjgnet.com/1007-9327/full/v15/i47/5946.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.5946